Time-dependent associations between iron and mortality in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 16, Issue 10, 2005, Pages 3070-3080

  Kalantar Zadeh, Kamyar ^a,b   Regidor, Deborah L ^a   McAllister, Charles J ^c   Michael, Beckie ^d   Warnock, David G ^e  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DAVITA INC   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; IRON;

ARTICLE; CACHEXIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALNUTRITION; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TIME; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; FEMALE; FERRITINS; HUMANS; INFLAMMATION; IRON; MALE; MALNUTRITION; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 33644824809     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005040423     Document Type: Article

References (50)

1. Pendse S, Singh AK: Complications of chronic kidney disease: Anemia, mineral metabolism, and cardiovascular disease. Med Clin North Am 89: 549-561, 2005
2. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lameire NH, Held PJ: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 44: 27-33, 2004
3. Triolo G, Canavese C, Di Giulio S: Reasons for producing guidelines on anemia of chronic renal failure: Dialysis outcome quality initiative of the National Kidney Foundation. Int J Artif Organs 21: 751-756, 1998
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
5. Moreno F, Aracil FJ, Perez R, Valderrabano F: Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 27: 548-556, 1996
6. Auer J, Simon G, Stevens J, Griffiths P, Howarth D, Anastassiades E, Gokal R, Oliver D: Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 12: 40-42, 1992
7. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 19: 561-565, 2004
8. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD: A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 43: 671-684, 2004
9. Kalantar-Zadeh K, Kleiner M, Dunne E, Ahern K, Nelson M, Koslowe R, Luft FC: Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31: 263-272, 1998
10. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004
11. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD: Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: The 58th annual fall conference and scientific sessions. Hypertension 45: 811-817, 2005
12. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S: Association of morbid obesity and weight change on cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005, in press
13. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H, Kopple JD, Greenland S: Revisiting outcome predictability of serum albumin in hemodialysis patients: Time dependency, changes over time and population attributable fraction. Nephrol Dialysis Transplant 2005, in press
14. Daugirdas JT: The post:pre-dialysis plasma urea nitrogen ratio to estimate K.t/V and NPCR: Validation. Int J Artif Organs 12: 420-427, 1989
15. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD: Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr 13: 15-25, 2003
16. National Kidney Foundation I, Kidney-Dialysis Outcome Quality Initiative: K/DOQI Clinical Practice Guidelines: Anemia of chronic kidney disease. Am J Kidney Dis 37[Suppl 1]: S182-S238, 2001
17. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: ii1-ii47, 2004
18. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD: Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42: 864-881, 2003
19. Shinaberger CS, Kilpatrick RD, McAllister CJ, Kopple JD, Kalantar-Zadeh K: Exploring time-dependent associations between urea dynamic calculated protein intake and cardiovascular mortality in hemodialysis patients [Abstract]. J Am Soc Nephrol 15[Suppl]: 385A-386A, 2004
20. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993
21. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 60: 333-340, 2001
22. Kalender B, Mutlu B, Ersoz M, Kalkan A, Yilmaz A: The effects of acute phase proteins on serum albumin, transferrin and haemoglobin in haemodialysis patients. Int J Clin Pract 56: 505-508, 2002
23. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK: Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol 14: 1000-1005, 2003
24. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
25. Wu DY, Kilpatrick RD, Dadres S, McAllister CJ, Kopple JD, Kalantar-Zadeh K: Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? 25th Dialysis Conference [Abstract]. Hemodial InI 9: 110, 2005
26. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF Jr, Lowrie EG: White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 18: 1167-1173, 2003
27. Kuwae N, Kopple J, Kalantar-Zadeh K: A low lymphocyte percentage is a predictor of mortality and hospitalization in hemodialysis patients. Clin Nephrol 63: 22-34, 2005
28. Wolfson M, Strong CJ, Minturn D, Gray DK, Kopple JD: Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 39: 547-555, 1984
29. Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG: Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant 19: 1576-1580, 2004
30. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextrantolerant patients. Kidney Int 63: 217-224, 2003
31. Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, Rothstein M, Strom J, Wolfe A, Van Wyck D, Yee J: Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int 66: 1193-1198, 2004
32. Yee J, Besarab A: Iron sucrose: The oldest iron therapy becomes new. Am J Kidney Dis 40: 1111-1121, 2002
33. Horl WH: Should we still use iron dextran in hemodialysis patients? Am J Kidney Dis 37: 859-861, 2001
34. Fletes R, Lazarus JM, Gage J, Chertow GM: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37: 743-749, 2001
35. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure-Time Data, 2nd Ed., New York, Wiley, 2002
36. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH: Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis 37: 564-572, 2001
37. Eschbach JW, Adamson JW: Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney Int Suppl 69: S35-S43, 1999
38. Kalantar-Zadeh K, Luft FC: Diagnosis of iron deficiency in ESRD patients. Am J Kidney Dis 30: 455-456, 1997
39. Neyra NR, Hakim RM, Shyr Y, Ikizler TA: Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. J Ren Nutr 10: 184-190, 2000
40. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH: Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 61: 319-322, 1989
41. Letendre ED: Iron metabolism during infection and neoplasia. Cancer Metastasis Rev 6: 41-53, 1987
42. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD: Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761-773, 2003
43. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002
44. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217, 2002
45. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13: 734-744, 2002
46. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623-1632, 2004
47. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 64: 572-578, 2003
48. Rothman K, Greenland S: Sources of bias. In: Modern Epidemiology, edited by Rothman K, Greenland S, Philadelphia, Lippincott-Raven, 1998
49. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
50. Barany P, Eriksson LC, Hultcrantz R, Pettersson E, Bergstrom J: Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 23: 273-276, 1997